Fundraising Fox
Syenex
Evanston, US · Founded 2022 · Delaware corporation · 17 employees on LinkedIn · 4 known investors
Find your way into Syenex
Sign up to see every warm intro you have to Syenex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Syenex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.
Founders & leadership
JD
John D. RosanelliExecutive
Investors · 4
AlleyCorplisted by AlleyCorpNew York · $1M – $5M
How we know: AlleyCorp's portfolio page · the VCSheet dataset · Not right? Tell us
Lightbanklisted by LightbankChicago · $500K – $5M
How we know: Lightbank's portfolio page · Not right? Tell us
Alley Robotics VenturesreportedCohasset · $500K – $2Mvia Abe Murray · inferred
How we know: the VCSheet dataset · Not right? Tell us
KdT VenturesreportedAustin · $500K – $3M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$13.7M disclosed across 2 rounds · 2022–2025
▶$8.7MraisedJan 2025 · 18 investors · BiotechnologyRule 506(b)
▶$8.7MraisedJan 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John D. RosanelliExecutive Officer, Director
- Offering amount
- $8.7M
- Amount sold
- $8.7M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$5MraisedSep 2022 · 14 investors · BiotechnologyRule 506(b)
▶$5MraisedSep 2022 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John D. RosanelliExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
XenexXenex builds pulsed Xenon UV light disinfection robots that deactivate pathogens missed during manual cleaning, used by hospitals to reduce environmental contamination and healthcare-associated infections. The company sells to hospital infection control programs as part of a device-plus-service offering.
Thumbnail for SyntheXSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.
Senex BiotechnologySenex Biotechnology develops cancer and chronic disease therapies by targeting aging-related biological pathways identified through functional genomics. The company focuses on oncology indications including ovarian, breast, and prostate cancers.
ScynexisSCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.
OncosenxOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Companies working in the same space as Syenex.
Frequently asked questions
- What does Syenex do?
- Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.
- Who are Syenex's investors?
- Syenex's investors include AlleyCorp, Lightbank, Alley Robotics Ventures, KdT Ventures.
- How much funding has Syenex raised?
- Syenex has disclosed $13.7M raised across 2 rounds.
- Where is Syenex headquartered?
- Syenex is headquartered in Evanston, US.